Technical Analysis for CNST - Constellation Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 26.21 -0.38% -0.10
CNST closed down 0.38 percent on Monday, March 8, 2021, on 63 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical CNST trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Earnings Movers Other 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup -0.38%
Wide Bands Range Expansion -0.38%
Up 3 Days in a Row Strength -0.38%
Oversold Stochastic Weakness -0.38%
Calm After Storm Range Contraction 1.04%
Older End-of-Day Signals for CNST ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above 10 DMA about 10 hours ago
10 DMA Resistance about 12 hours ago
Up 3% about 12 hours ago
60 Minute Opening Range Breakout about 12 hours ago
Up 2% about 12 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Constellation Pharmaceuticals, Inc. Description

Constellation Pharmaceuticals, Inc. is a United States-based company, which discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has two clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, and the other program is evaluating a compound, CPI-1205. CPI-0610 is a small molecule that inhibits the binding of bromodomain and extra terminal (BET) proteins to chromatin. CPI-1205 is a small molecule that inhibits an enzyme, Enhancer of Zeste Homolog 2 (EZH2). It is in a Phase I clinical study of CPI-0610 in patients with progressive lymphoma; a Phase I clinical study of CPI-0610 in patients with acute leukemia, myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasms; a Phase I clinical study of CPI-0610 in patients with previously treated multiple myeloma, and a Phase 1 clinical study of CPI-1205 in patients with lymphoma.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Diseases Treatment Of Cancer Lymphoma Multiple Myeloma Myelodysplastic Syndrome Constellation Progressive Molecule Therapeutics Acute Leukemia Neoplasms Chromatin Ezh2 Myeloproliferative Neoplasm

Is CNST a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 50.8883
52 Week Low 17.0
Average Volume 461,505
200-Day Moving Average 27.57
50-Day Moving Average 31.59
20-Day Moving Average 31.43
10-Day Moving Average 27.08
Average True Range 2.40
ADX 30.85
+DI 15.15
-DI 28.11
Chandelier Exit (Long, 3 ATRs ) 30.91
Chandelier Exit (Short, 3 ATRs ) 31.19
Upper Bollinger Band 41.27
Lower Bollinger Band 21.58
Percent B (%b) 0.24
BandWidth 62.66
MACD Line -2.03
MACD Signal Line -1.21
MACD Histogram -0.8178
Fundamentals Value
Market Cap 1.25 Billion
Num Shares 47.6 Million
EPS -3.13
Price-to-Earnings (P/E) Ratio -8.39
Price-to-Sales 0.00
Price-to-Book 2.77
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.49
Resistance 3 (R3) 28.59 27.94 28.11
Resistance 2 (R2) 27.94 27.36 27.89 27.98
Resistance 1 (R1) 27.07 27.00 26.75 26.97 27.86
Pivot Point 26.42 26.42 26.25 26.37 26.42
Support 1 (S1) 25.55 25.84 25.23 25.45 24.56
Support 2 (S2) 24.90 25.48 24.85 24.44
Support 3 (S3) 24.03 24.90 24.31
Support 4 (S4) 23.93